Report in The Lancet Further Boosts Interest in Weight-Loss Drug Acomplia
A report published in this week’s issue of the prestigious medical journal, The Lancet, further stoked interest in the promising new weight-loss drug Acomplia (rimonabant) but in fact provided little new information.
The report was based on one-year results from the RIO–Europe clinical trial, which showed [...]
Support for “Metabolic Syndrome” May Buttress Expanded Role for Acomplia
The American Heart Association (AHA) and the National Heart, Lung and Blood Institute (NHLBI) on Sept. 13 issued a new scientific statement taking issue with two major diabetes organizations Acomplia (rimonabant) that a month ago questioned the validity of diagnosing patients with “metabolic syndrome.”
The debate could well impact efforts of [...]
Experimental Obesity Drug APD356 Reported Effective in Small, Short Trial
A year ago at this time, millions of overweight and obese An experimental drug for the treatment of obesity, APD356, reportedly produced encouraging results in a relatively small four week clinical trial, according to a statement released by Arena Pharmaceuticals, Inc Acomplia (rimonabant) .
Arena said [...]
Survey: Two Thirds of Doctors Likely to Prescribe Acomplia for Obesity
Two out of three doctors say they are likely to prescribe Acomplia (rimonabant) to treat patients with obesity after the new drug is approved by the U.S. Food and Drug Administration, according to a new research study.
Decision Resources, Inc., a leading research and advisory firm [...]
New Acomplia News Will Be Presented on March 8th
After a four-month dry spell during which there has been little news about development of the highly publicized obesity drug Acomplia (rimonabant) , researchers are scheduled to present new data from the RIO–Europe clinical trial at a scientific meeting in Orlando on Tuesday, March 8th.
The presentation of the [...]
Study: Acomplia Increases the Likelihood of Success in Quitting Smoking
Researchers at the University of Cincinnati Acomplia (rimonabant) College of Medicine presented results of one of the largest smoking cessation trials ever conducted in the United States, STRATUS-US (STudies with Rimonabant And Tobacco USe). The findings show that a new drug, rimonabant, doubled the odds of quitting [...]
Causes of Obesity-Environmental Factors
Causes of Obesity-Environmental Factors
Along with genetics, environmental factors have been found to contribute to obesity. In particular, increased food consumptionand an inactive (sedentary) lifestyle are environmental factors that very closely correlate with an increased risk of obesity.Americans have an ever-increasing number of energydense foods, packaged in enormous portions, conveniently available at low [...]
Encouraging Results Expected in Report June 12th on RIO-Diabetes Trial
Another round of good news about the diet–drug Acomplia (rimonabant) seems likely to be forthcoming on June 12th when researchers publicly report for the first time on results of the RIO-Diabetes trial at the American Diabetes Association’s annual scientific meeting in San Diego.
The year-long Rimonabant in [...]
